
BCYC Stock Forecast & Price Target
BCYC Analyst Ratings
Bulls say
Bicycle Therapeutics PLC is demonstrating a robust pipeline, particularly with its product candidate BT1718, as indicated by positive feedback from key opinion leaders (KOLs) who recognize its competitive advantages over established therapies like Padcev. The company's innovative Bicycles, designed to target oncology indications with significant unmet medical needs, position it favorably within an evolving biopharmaceutical landscape. Additionally, BCYC's focus on delivering safe and effective outcomes while maintaining lower system costs enhances its potential for generating substantial revenue, primarily from its stronger market presence in the United States.
Bears say
Bicycle Therapeutics PLC has faced significant stock pressure, with shares down 45% year-to-date, primarily due to investor concerns over equivocal clinical data amid a challenging market environment. The risk of safety issues or poor efficacy related to its product candidate Zelenectide highlights potential for further downside, estimated at 25% if these concerns materialize. Additionally, the stock is currently trading below cash, indicating investor skepticism regarding the company's unique approach and the viability of its pipeline in oncology.
This aggregate rating is based on analysts' research of Bicycle Therapeutics Plc - ADR and is not a guaranteed prediction by Public.com or investment advice.
BCYC Analyst Forecast & Price Prediction
Start investing in BCYC
Order type
Buy in
Order amount
Est. shares
0 shares